by Louiza | Oct 1, 2023 | News
Updates – October 2023 Annogen is excited to share our latest break through in cellular engineering. We’ve successfully combined our SuRE™ promoter screening platform and our AIM™ integration site screening platform to establish HEK293 clones with...
by Louiza | Mar 1, 2023 | News
News – March 2023 AIM™ service (Annogen Integration Mapping: integration sites and their expression levels) was introduced in 2022 supporting cell engineering for cell therapy development. Now it is also available to the contract manufacturing market: manufacturing...
by Louiza | Jan 26, 2023 | News
PRESS RELEASE Annogen, The Netherlands, 26 January 2023 — the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with another top agricultural science and...
by Louiza | Jan 19, 2023 | News
PRESS RELEASE Amsterdam, The Netherlands, 19 January 2023 Annogen to develop multiple CNS-cell specific promoters for VectorY programs VectorY Therapeutics, a biotech company developing innovative vectorized antibody approaches for the treatment of neurodegenerative...
by Louiza | Dec 13, 2022 | News
PRESS RELEASE Annogen will functionally annotate tens of thousands of disease-related non-coding sequence variants with the goal of aiding drug discovery. AMSTERDAM, 13 December 2022 — Annogen, the Amsterdam based biotech company behind the SuRE™ technology for...
by Louiza | Jun 25, 2022 | News
Identify favorable gene insertions and their expression levels (> 100,000 integrations in parallel) Annogen introduces a new service to identify gene insertions and asses their expression levels for >100,000 integrations in parallel. Using an adaptation of its...
